Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Primary Purpose
Cancer
Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Denileukin diftitox (ONTAK)
Sponsored by

About this trial
This is an expanded access trial for Cancer focused on measuring Cancer, ONTAK, Denileukin diftitox, persistent or recurrent disease, requiring continued delivery of essential cancer therapy
Eligibility Criteria
Inclusion Criteria:
To receive denileukin diftitox (ONTAK) under this protocol, the patient's physician must request this therapy for the specific patient. Patients may continue treatment with denileukin diftitox if they:
- Are currently on therapy with denileukin diftitox and require ongoing therapy to maintain control of their disease.
- Are willing and able to comply with all aspects of the Access Protocol
- Provide written informed consent to participate
Exclusion Criteria:
Patients are not eligible for the Access Program with denileukin diftitox if they:
• Are not currently on denileukin diftitox therapy
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01432483
Brief Title
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Official Title
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Study Type
Expanded Access
2. Study Status
Record Verification Date
January 2015
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eisai Inc.
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to provide continued therapy with Denileukin diftitox (ONTAK) to patients who are currently on therapy and who have no other suitable treatment options, where therapy is requested by their physician.
Detailed Description
The Access Program will be provided as long as appropriate according to the judgment of the provider. If Denileukin diftitox (ONTAK) becomes commercially available without restriction, then the access program will be discontinued.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer
Keywords
Cancer, ONTAK, Denileukin diftitox, persistent or recurrent disease, requiring continued delivery of essential cancer therapy
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Denileukin diftitox (ONTAK)
Other Intervention Name(s)
ONTAK
Intervention Description
Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.
10. Eligibility
Sex
All
Eligibility Criteria
Inclusion Criteria:
To receive denileukin diftitox (ONTAK) under this protocol, the patient's physician must request this therapy for the specific patient. Patients may continue treatment with denileukin diftitox if they:
Are currently on therapy with denileukin diftitox and require ongoing therapy to maintain control of their disease.
Are willing and able to comply with all aspects of the Access Protocol
Provide written informed consent to participate
Exclusion Criteria:
Patients are not eligible for the Access Program with denileukin diftitox if they:
• Are not currently on denileukin diftitox therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gary Palmer, MD
Organizational Affiliation
Eisai Inc.
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
We'll reach out to this number within 24 hrs